Neogenomics Stock Today
| NEO Stock | USD 10.88 0.29 2.60% |
PerformanceVery Weak
| Odds Of DistressBelow Average
|
NeoGenomics is selling at 10.88 as of the 26th of February 2025; that is 2.6 percent decrease since the beginning of the trading day. The stock's open price was 11.17. NeoGenomics has about a 37 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 27th of January 2025 and ending today, the 26th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of November 1999 | Category Healthcare | Classification Health Care |
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company was founded in 2001 and is headquartered in Fort Myers, Florida. Neogenomics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. The company has 128.46 M outstanding shares of which 3.77 M shares are now shorted by investors with about 3.25 days to cover. More on NeoGenomics
Moving together with NeoGenomics Stock
Moving against NeoGenomics Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
NeoGenomics Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President | William Bonello | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Quadient SAS | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Life Sciences Tools & Services, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsNeoGenomics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand NeoGenomics' financial leverage. It provides some insight into what part of NeoGenomics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NeoGenomics (NEO) is traded on NASDAQ Exchange in USA. It is located in 9490 NeoGenomics Way, Fort Myers, FL, United States, 33912 and employs 2,200 people. NeoGenomics is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a total capitalization of 1.4 B. NeoGenomics runs under Life Sciences Tools & Services sector within Health Care industry. The entity has 128.46 M outstanding shares of which 3.77 M shares are now shorted by investors with about 3.25 days to cover.
NeoGenomics has about 465.95 M in cash with 7.02 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.7.
Check NeoGenomics Probability Of Bankruptcy
Ownership AllocationNeoGenomics maintains a total of 128.46 Million outstanding shares. The majority of NeoGenomics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in NeoGenomics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in NeoGenomics. Please pay attention to any change in the institutional holdings of NeoGenomics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check NeoGenomics Ownership Details
NeoGenomics Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-12-31 | 3 M | |
| American Century Companies Inc | 2024-12-31 | 2.9 M | |
| Goldman Sachs Group Inc | 2024-12-31 | 2.3 M | |
| Segall Bryant & Hamill | 2024-12-31 | 2.1 M | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.8 M | |
| Loomis, Sayles & Company Lp | 2024-12-31 | 1.8 M | |
| Fred Alger Management, Llc | 2024-12-31 | 1.7 M | |
| Northern Trust Corp | 2024-12-31 | 1.6 M | |
| Emerald Advisers, Llc | 2024-12-31 | 1.6 M | |
| Blackrock Inc | 2024-12-31 | 20.2 M | |
| Vanguard Group Inc | 2024-12-31 | 14.2 M |
NeoGenomics Historical Income Statement
NeoGenomics Stock Against Markets
NeoGenomics Corporate Management
| Facmg MBA | Pres Officer | Profile | |
| Nathan MD | Vice Services | Profile | |
| George Cardoza | Pres Operations | Profile | |
| Kareem Saad | Head Transformation | Profile | |
| Gary Passman | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.306 | Earnings Share (0.62) | Revenue Per Share | Quarterly Revenue Growth 0.106 | Return On Assets |
The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.